/

SRNE

Sorrento Therapeutics, Inc.Closed

0.000600−0.00 −25.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.009000

Prev close

0.000800

Day range

0.0090000.0100

52-week range

0.0001000.0160

Volume

501.68K4.48×

Mkt cap

330.77K

P/E ttm

—

Fwd P/E

—

EPS ttm

-1.34

Div yield

0.00%

Earnings

—

From 52w high

−96.25%

Price Chart

Yahoo Finance · delayed

SRNEOct 12, 2026O 0.0008H 0.0010L 0.0001C 0.0006−0.0002 (−25.00%)Vol 149.14K

SMA 500.0006
SMA 2000.0015

1Y change −88.00% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SRNE Sorrento Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −25.00%
1 month: +50.00%
3 months: −14.29%
6 months: −14.29%
Year to date: −76.92%
1 year: −89.09%

Valuation & ownership

Market cap: 330.77K
Enterprise value: 134.29M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): 0.01
EV / EBITDA: -0.39
EPS (ttm): -1.34
EPS (forward): —
Beta (5y monthly): -0.01
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 551.28M
Float: 539.11M
Short % of float: 11.96%
Short ratio (days): 4.96
Held by insiders: 0.00%
Held by institutions: 0.04%
Avg volume (3m): 111.99K
50-day average: 0.000620
200-day average: 0.001502
52-week change: −89.09%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 43.5
vs 50-day SMA: −2.91%
vs 200-day SMA: −61.12%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 52.45%
Realised vol (20d, ann.): 291.2%
From 52-week high: −96.25%
From 52-week low: +500.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 64.27M
Revenue growth (yoy): +31.10%
Earnings growth (yoy): —
Gross margin: -245.01%
Operating margin: -510.93%
Profit margin: 0.00%

DES

About Sorrento Therapeutics, Inc.

Yahoo Finance profile

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Sector: Healthcare
Industry: Biotechnology
Employees: 949
Headquarters: San Diego, CA, United States
Website: sorrentotherapeutics.com
Officers: Dr. Henry H. Ji Ph.D. Chairman, President & CEO
Dr. Scott Schaus Ph.D. Chief Technology Officer

SEAS

Seasonality · SRNE

2007–2026 · monthly returns

Strongest month Jul +40.39%Weakest month Sep −8.51%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.8	-36.0	106.3	-75.8	-37.5	20.0	-16.7	0.0	60.0	-25.0			−76.9%
2025	-20.0	25.0	40.0	28.6	44.4	7.7	7.1	300.0	-41.7	122.9	1.3	-67.1	+420.0%
2024	-65.6	-36.5	-70.4	100.0	-29.4	-15.9	-21.1	-20.0	-33.3	-32.5	-44.4	-66.7	−99.6%
2023	8.2	-68.2	18.0	-13.9	0.4	15.0	-9.2	-59.4	-28.8	-39.0	-21.5	174.4	−86.1%
2022	-25.8	-26.7	-7.9	-35.2	8.6	22.6	29.4	-21.2	-23.4	0.0	-17.2	-31.8	−80.9%
2021	85.5	-23.6	-14.5	-0.5	-8.6	28.9	-15.3	9.6	-15.2	-10.1	-13.1	-22.0	−31.9%
2020	13.3	-43.3	-15.2	23.4	122.5	24.4	42.0	-10.2	39.2	-37.8	18.2	-16.8	+101.9%
2019	-14.2	-1.5	134.0	-23.2	-23.0	-5.0	0.7	-21.6	1.4	-29.0	92.1	15.8	+40.8%
2018	94.7	34.5	-48.2	19.4	27.6	-8.3	-22.2	-0.9	-20.7	-27.5	8.5	-30.6	−36.8%
2017	10.2	-3.7	-24.0	-50.6	-20.5	29.0	-2.5	-7.7	-5.6	55.9	-15.1	68.9	−22.4%
2016	-39.7	15.0	-10.9	27.5	1.5	-19.5	12.3	5.9	16.2	-25.7	-8.7	-6.7	−43.7%
2015	0.2	28.0	-10.5	-22.0	52.9	27.8	17.9	-39.0	-33.8	3.0	-7.3	8.7	−13.5%
2014	17.9	20.6	11.3	-28.3	-43.3	29.6	-19.4	1.1	-17.8	-6.6	-8.8	161.6	+24.3%
2013	66.7	-19.6	-0.5	7.5	-7.0	45.0	3.4	2.7	24.5	0.1	-8.3	-8.0	+116.0%
2012	25.0	56.0	51.3	-23.7	-48.9	17.4	-44.4	50.0	11.1	-4.0	-8.3	-31.8	−25.0%
2011	-50.0	0.0	0.0	0.0	0.0	0.0	-23.3	0.0	0.0	0.0	-4.3	-9.1	−66.7%
2010	0.0	-8.9	70.9	0.3	-42.0	0.6	0.0	0.0	0.0	-5.7	-63.6	0.0	−68.8%
2009	0.0	0.0	-77.8	0.0	0.0	0.0	850.0	6.3	-50.5	0.0	-36.0	500.0	+326.7%
2008	6.7	-6.3	-13.3	0.0	-23.1	30.0	-23.1	20.0	-16.7	1.0	0.0	-55.4	−70.0%
2007	-100.0	-70.0	316.7	20.0	-6.7	-28.6	-15.0	-11.8	33.3	-10.0	-12.9	-4.3	−100.0%

SRNE

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SRNE

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Sorrento Therapeutics, Inc.

Seasonality · SRNE

Insider Activity · SRNE

Congress Trades · SRNE

Investors Holding SRNE

Investors Holding SRNE

Congress Trades · SRNE

Insider Activity · SRNE

Seasonality · SRNE

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Sorrento Therapeutics, Inc.

Earnings & Dividends

News